根据抗真菌药敏试验欧洲委员会药敏试验分会制定的折点，西班牙念珠菌属临床分离株体外伏立康唑耐药率。
Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.
机构信息
Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo Km. 2, 28220 Majadahonda (Madrid), Spain.
出版信息
Antimicrob Agents Chemother. 2011 Apr;55(4):1794-7. doi: 10.1128/AAC.01757-10. Epub 2011 Jan 31.
Abstract
A total of 4,226 Spanish clinical isolates of Candida spp. were analyzed to assess resistance to voriconazole according to breakpoints established by the European Committee for Antimicrobial Susceptibility Testing (where susceptibility [S] to voriconazole corresponds to a MIC of ≤ 0.12 mg/liter). Resistance was uncommon among Candida albicans (5%), C. parapsilosis (1.2%), and C. tropicalis (11%) isolates. Voriconazole MICs of >0.12 mg/liter were more frequent among Candida glabrata and C. krusei isolates. A significant percentage of voriconazole-resistant strains came from oropharyngeal infections and exhibited high MICs of other azoles.
摘要
共分析了 4226 株西班牙念珠菌属临床分离株，以评估根据欧洲抗菌药物敏感性试验委员会（其中对伏立康唑的敏感性[S]对应于 MIC≤0.12 毫克/升）建立的折点对伏立康唑的耐药性。白念珠菌（5%）、近平滑念珠菌（1.2%）和热带念珠菌（11%）分离株的耐药性并不常见。伏立康唑 MIC 值>0.12 毫克/升在光滑念珠菌和克柔念珠菌分离株中更为常见。来自口咽感染的具有显著百分比的伏立康唑耐药菌株和表现出其他唑类药物高 MIC 值。
相似文献
1
Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.
Antimicrob Agents Chemother. 2011 Apr;55(4):1794-7. doi: 10.1128/AAC.01757-10. Epub 2011 Jan 31.
2
[Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Mikrobiyol Bul. 2016 Jan;50(1):122-32. doi: 10.5578/mb.10682.
3
In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Eur J Clin Microbiol Infect Dis. 2004 Aug;23(8):619-24. doi: 10.1007/s10096-004-1174-9. Epub 2004 Jul 16.
4
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Clin Microbiol Infect. 2014 Jul;20(7):698-705. doi: 10.1111/1469-0691.12440. Epub 2013 Dec 12.
5
Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
J Clin Microbiol. 2011 Feb;49(2):630-7. doi: 10.1128/JCM.02161-10. Epub 2010 Dec 15.
6
[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rev Esp Quimioter. 2003 Jun;16(2):227-32.
7
In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
J Mycol Med. 2018 Jun;28(2):310-313. doi: 10.1016/j.mycmed.2018.03.005.
8
Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.
J Clin Microbiol. 2009 Jun;47(6):1927-30. doi: 10.1128/JCM.02070-08. Epub 2009 Apr 29.
9
Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
J Clin Microbiol. 2008 Sep;46(9):2902-5. doi: 10.1128/JCM.00937-08. Epub 2008 Jul 16.
10
Candida and candidaemia. Susceptibility and epidemiology.
Dan Med J. 2013 Nov;60(11):B4698.
引用本文的文献
1
Twenty-Year Course of Antifungal Resistance in in Türkiye: A Systematic Review and Meta-Analysis.
J Fungi (Basel). 2025 Aug 19;11(8):603. doi: 10.3390/jof11080603.
2
Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae041.
3
D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections.
Sci Rep. 2018 Jun 18;8(1):9235. doi: 10.1038/s41598-018-27417-x.
4
Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.
BMC Infect Dis. 2017 Nov 21;17(1):727. doi: 10.1186/s12879-017-2825-7.
5
Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.
Folia Microbiol (Praha). 2017 Nov;62(6):525-530. doi: 10.1007/s12223-017-0525-8. Epub 2017 Mar 30.
6
The susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspofungin.
Jundishapur J Microbiol. 2015 Mar 21;8(3):e24298. doi: 10.5812/jjm.24298. eCollection 2015 Mar.
7
Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey.
Mycopathologia. 2014 Oct;178(3-4):243-50. doi: 10.1007/s11046-014-9791-z. Epub 2014 Aug 8.
8
Epidemiology of invasive fungal infections in the mediterranean area.
Mediterr J Hematol Infect Dis. 2011;3(1):e20110016. doi: 10.4084/mjhid.2011.0016. Epub 2011 Mar 31.
本文引用的文献
1
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
Drug Resist Updat. 2010 Dec;13(6):180-95. doi: 10.1016/j.drup.2010.09.002. Epub 2010 Nov 2.
2
EUCAST breakpoints for antifungals.
Drug News Perspect. 2010 Mar;23(2):93-7. doi: 10.1358/dnp.2010.23.2.1400855.
3
Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods.
J Clin Microbiol. 2010 May;48(5):1895-9. doi: 10.1128/JCM.00336-10. Epub 2010 Mar 17.
4
The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.
Expert Rev Anti Infect Ther. 2010 Mar;8(3):267-76. doi: 10.1586/eri.10.2.
5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
Antimicrob Agents Chemother. 2009 May;53(5):2192-5. doi: 10.1128/AAC.01543-08. Epub 2009 Feb 17.
6
Antifungal therapeutic drug monitoring: established and emerging indications.
Antimicrob Agents Chemother. 2009 Jan;53(1):24-34. doi: 10.1128/AAC.00705-08. Epub 2008 Oct 27.
7
EUCAST Technical Note on voriconazole.
Clin Microbiol Infect. 2008 Oct;14(10):985-7. doi: 10.1111/j.1469-0691.2008.02087.x.
8
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.
Clin Microbiol Infect. 2008 Apr;14(4):398-405. doi: 10.1111/j.1469-0691.2007.01935.x. Epub 2008 Jan 11.
9
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Clin Infect Dis. 2008 Jan 15;46(2):201-11. doi: 10.1086/524669.
10
Epidemiology of invasive candidiasis: a persistent public health problem.
Clin Microbiol Rev. 2007 Jan;20(1):133-63. doi: 10.1128/CMR.00029-06.
Zotero 插件